A phase I open-label study of the safety and efficacy of apatinib (rivoceranib) administered to patients with advanced malignancies to improve sensitivity to pembrolizumab in the second- or later-line setting (APPEASE)

OBJECTIVE: APPEASE is a phase I study to assess the safety, dosing, and efficacy of rivoceranib (a selective, small-molecule inhibitor of VEGFR2) in combination with pembrolizumab. We aimed to treat patients with metastatic malignancies who have progressed through at least first-line therapy, with p...

Descripción completa

Detalles Bibliográficos
Autores principales: Gumbleton, Matthew, Allan, Stephanie, Conway, Hannah, Boucher, Kenneth, Marvin, James, Hawks, Josiah, Burnett, William, Van Brocklin, Matthew, Whisenant, Jonathan, Gilcrease, Glynn, Gupta, Sumati
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research Note
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9936706/
https://www.ncbi.nlm.nih.gov/pubmed/36797744
http://dx.doi.org/10.1186/s13104-023-06283-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9936706/
https://www.ncbi.nlm.nih.gov/pubmed/36797744
http://dx.doi.org/10.1186/s13104-023-06283-5

Ejemplares similares